Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Prostatic Neoplasms, Castration-Resistant
  • Quinolones

abstract

  • In chemotherapy-naïve men with mCRPC, tasquinimod significantly improved rPFS compared with placebo. However, no OS benefit was observed.

publication date

  • August 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2016.66.9697

PubMed ID

  • 27298414

Additional Document Info

start page

  • 2636

end page

  • 43

volume

  • 34

number

  • 22